| 1.11 -0.01 (-0.89%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.32 |
1-year : | 1.36 |
| Resists | First : | 1.13 |
Second : | 1.16 |
| Pivot price | 1.12 |
|||
| Supports | First : | 1.07 |
Second : | 0.89 |
| MAs | MA(5) : | 1.11 | MA(20) : | 1.12 |
| MA(100) : | 1.11 |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 43.3 | D(3) : | 44.4 |
| RSI | RSI(14): 47.1 |
|||
| 52-week | High : | 1.5 | Low : | 0.99 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ENZ ] has closed above bottom band by 24.0%. Bollinger Bands are 54.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.14 - 1.15 | 1.15 - 1.15 |
| Low: | 1.1 - 1.1 | 1.1 - 1.11 |
| Close: | 1.1 - 1.11 | 1.11 - 1.12 |
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Tue, 13 Aug 2024
Enzo Biochem penalized $4.5M over data breach - Seeking Alpha
Thu, 25 Jul 2024
Enzo Biochem Enhances CFO Patricia Eckert’s Compensation Package - TipRanks
Wed, 17 Jul 2024
Enzo Biochem: Is This Time Finally Different? - Seeking Alpha
Thu, 13 Jun 2024
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update - GlobeNewswire
Wed, 10 Apr 2024
Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Markets Insider
Tue, 27 Feb 2024
Enzo Biochem Executives Receive Raises and Equity Rewards - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 51 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 24 (%) |
| Held by Institutions | 31.9 (%) |
| Shares Short | 504 (K) |
| Shares Short P.Month | 532 (K) |
| EPS | -0.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.35 |
| Profit Margin | 134.1 % |
| Operating Margin | -25.5 % |
| Return on Assets (ttm) | -12.8 % |
| Return on Equity (ttm) | -40 % |
| Qtrly Rev. Growth | 7.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.64 |
| EBITDA (p.s.) | -0.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -42 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -3.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.82 |
| Price to Sales | 1.71 |
| Price to Cash Flow | -1.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|